Comparative Effectiveness of rhTPO and TPO Receptor Agonists in Severe, Refractory Immune Thrombocytopenia during Pregnancy: A Retrospective Analysis
Authors:
Preprint
- 10 August 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Objective To evaluate the efficacy and safety of recombinant human thrombopoietin (rhTPO), thrombopoietin receptor agonists (TPO-RAs), and their combination in pregnant patients with refractory severe immune thrombocytopenia (ITP) (platelet count < 30×10⁹/L,unresponsive to first-line corticosteroids/intravenous immunoglobulin [IVIG]). Methods This retrospective study enrolled 28 pregnant patients with severe ITP. Patients were assigned to three groups: rhTPO monotherapy (n = 16), TPO-RA monotherapy (eltrombopag, hetrombopag, or avatrombopag; n = 3), or combined rhTPO + TPO-RA therapy (n = 9). Efficacy (complete/partial/no response) was assessed 2 weeks post-treatment per standardized criteria. Safety (maternal adverse events, neonatal outcomes) and obstetric outcomes (gestational age at delivery, mode of delivery, postpartum hemorrhage) were analyzed. Results TPO-RA monotherapy achieved a 100% response rate (1 CR, 2 PR); rhTPO monotherapy had a 25% response rate (2 CR, 2 PR); combined therapy showed 0% response. No serious maternal adverse events occurred except 1 case of mild eltrombopag-related liver function impairment (resolved after switching to hetrombopag). Excluding 3 second-trimester medical inductions for treatment failure, 25 singleton live births were recorded, with only 1 neonate having thrombocytopenia (no severe neonatal complications). Conclusion TPO-RAs exhibit a favorable safety profile and promising efficacy in patients with refractory severe ITP, whereas rhTPO demonstrates a suboptimal response. Combined rhTPO + TPO-RAs therapy showed no responses, likely due to selection bias; thus, it is not routinely recommended, and sequential therapy (e.g., TPO-RA after rhTPO failure) may be a more rational approach. This study provides valuable insights for clinical decision-making in the absence of standardized second-line guidelines for gestational ITP, though large multicenter validation is needed.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and managementExpert Review of Hematology, 2024
- Knowledge map of thrombopoietin receptor agonists: A bibliometric analysisHeliyon, 2024
- Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonistsBritish Journal of Haematology, 2023
- 2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancyChinese Medical Journal, 2022
- ACOG Practice Bulletin No. 207: Thrombocytopenia in PregnancyObstetrics & Gynecology, 2019
- First line treatment of adult patients with primary immune thrombocytopenia: a real-world studyPlatelets, 2019
- Neonates born to mothers with immune thrombocytopeniaBlood Coagulation & Fibrinolysis, 2018
- Optimised glucocorticoid therapy: the sharpening of an old spearThe Lancet, 2005
- Idiopathic thrombocytopenic purpura complicating pregnancyBlood Reviews, 2002
- Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpuraThe American Journal of Medicine, 1995